These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 36089245)

  • 1. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
    Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Sáez-Martínez P; Fuentes-Fayos AC; Closa A; González-Serrano T; Martínez-López A; Sánchez-Sánchez R; López-Casas PP; Sarmento-Cabral A; Olmos D; Eyras E; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2023 Mar; 253():68-79. PubMed ID: 36089245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
    Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
    Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
    Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
    Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
    Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative splicing of NF-YA promotes prostate cancer aggressiveness and represents a new molecular marker for clinical stratification of patients.
    Belluti S; Semeghini V; Rigillo G; Ronzio M; Benati D; Torricelli F; Reggiani Bonetti L; Carnevale G; Grisendi G; Ciarrocchi A; Dominici M; Recchia A; Dolfini D; Imbriano C
    J Exp Clin Cancer Res; 2021 Nov; 40(1):362. PubMed ID: 34782004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RBM22, a Key Player of Pre-mRNA Splicing and Gene Expression Regulation, Is Altered in Cancer.
    Soubise B; Jiang Y; Douet-Guilbert N; Troadec MB
    Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer.
    Hormaechea-Agulla D; Jiménez-Vacas JM; Gómez-Gómez E; L-López F; Carrasco-Valiente J; Valero-Rosa J; Moreno MM; Sánchez-Sánchez R; Ortega-Salas R; Gracia-Navarro F; Culler MD; Ibáñez-Costa A; Gahete MD; Requena MJ; Castaño JP; Luque RM
    FASEB J; 2017 Nov; 31(11):4682-4696. PubMed ID: 28705809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intron retention is a hallmark and spliceosome represents a therapeutic vulnerability in aggressive prostate cancer.
    Zhang D; Hu Q; Liu X; Ji Y; Chao HP; Liu Y; Tracz A; Kirk J; Buonamici S; Zhu P; Wang J; Liu S; Tang DG
    Nat Commun; 2020 Apr; 11(1):2089. PubMed ID: 32350277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysine Demethylase 6B Regulates Prostate Cancer Cell Proliferation by Controlling c-MYC Expression.
    Yıldırım-Buharalıoğlu G
    Mol Pharmacol; 2022 Feb; 101(2):106-119. PubMed ID: 34862309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin.
    Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo.
    Kiener M; Chen L; Krebs M; Grosjean J; Klima I; Kalogirou C; Riedmiller H; Kneitz B; Thalmann GN; Snaar-Jagalska E; Spahn M; Kruithof-de Julio M; Zoni E
    BMC Cancer; 2019 Jun; 19(1):627. PubMed ID: 31238903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer.
    Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Sáez-Martínez P; Gómez-Gómez E; León-González AJ; Fuentes-Fayos AC; Yubero-Serrano EM; Requena-Tapia MJ; López M; Castaño JP; Gahete MD; Luque RM
    J Clin Endocrinol Metab; 2021 Jan; 106(2):e696-e710. PubMed ID: 33247590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Krüppel-like factor 8 is a novel androgen receptor co-activator in human prostate cancer.
    He HJ; Gu XF; Xu WH; Yang DJ; Wang XM; Su Y
    Acta Pharmacol Sin; 2013 Feb; 34(2):282-8. PubMed ID: 23023312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Splice Variant of the Inhibitor of Growth 3 Lacks the Plant Homeodomain and Regulates Epithelial-Mesenchymal Transition in Prostate Cancer Cells.
    Melekhova A; Leeder M; Pungsrinont T; Schmäche T; Kallenbach J; Ehsani M; Mirzakhani K; Rasa SMM; Neri F; Baniahmad A
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
    Cai Y; Balli D; Ustiyan V; Fulford L; Hiller A; Misetic V; Zhang Y; Paluch AM; Waltz SE; Kasper S; Kalin TV
    J Biol Chem; 2013 Aug; 288(31):22527-41. PubMed ID: 23775078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
    Sáez-Martínez P; Porcel-Pastrana F; Montero-Hidalgo AJ; Lozano de la Haba S; Sanchez-Sanchez R; González-Serrano T; Gómez-Gómez E; Martínez-Fuentes AJ; Jiménez-Vacas JM; Gahete MD; Luque RM
    Cancer Lett; 2024 Mar; 584():216604. PubMed ID: 38244911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.
    Maynard JP; Lu J; Vidal I; Hicks J; Mummert L; Ali T; Kempski R; Carter AM; Sosa RY; Peiffer LB; Joshu CE; Lotan TL; De Marzo AM; Sfanos KS
    J Pathol; 2022 Feb; 256(2):149-163. PubMed ID: 34652816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
    Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
    J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host versus cell-dependent effects of β-arrestin 1 expression in prostate tumorigenesis.
    Adekoya TO; Smith N; Thomas AJ; Lane TS; Burnette N; Rivers EJ; Li Y; Chen XL; Richardson RM
    Carcinogenesis; 2021 May; 42(5):772-783. PubMed ID: 33710266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.